Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | G protein coupled receptor 139 | 0.0136745 | 0.0267189 | 0.0267189 |
Plasmodium vivax | topoisomerase I, putative | 0.405754 | 1 | 1 |
Echinococcus multilocularis | neuropeptide receptor | 0.0136745 | 0.0267189 | 0.0267189 |
Schistosoma mansoni | neuropeptide receptor | 0.0136745 | 0.0267189 | 0.0267189 |
Trichomonas vaginalis | prokaryotic DNA topoisomerase, putative | 0.002911 | 0 | 0.5 |
Plasmodium falciparum | topoisomerase I | 0.405754 | 1 | 1 |
Treponema pallidum | DNA topoisomerase I (topA) | 0.002911 | 0 | 0.5 |
Echinococcus granulosus | neuropeptide receptor | 0.0136745 | 0.0267189 | 0.0267189 |
Trypanosoma brucei | DNA topoisomerase IB, large subunit | 0.299126 | 0.735311 | 1 |
Loa Loa (eye worm) | CAMK/CAMKL/CHK1 protein kinase | 0.0220261 | 0.0474506 | 0.0474506 |
Brugia malayi | DNA topoisomerase I | 0.405754 | 1 | 1 |
Trypanosoma cruzi | DNA topoisomerase type IB small subunit, putative | 0.198187 | 0.484744 | 0.659237 |
Giardia lamblia | DNA topoisomerase III | 0.002911 | 0 | 0.5 |
Leishmania major | DNA topoisomerase type IB small subunit | 0.198187 | 0.484744 | 0.659237 |
Schistosoma mansoni | DNA topoisomerase type I | 0.299126 | 0.735311 | 0.735311 |
Trypanosoma cruzi | DNA topoisomerase IB, large subunit, putative | 0.299126 | 0.735311 | 1 |
Toxoplasma gondii | DNA topoisomerase I, putative | 0.405754 | 1 | 1 |
Echinococcus multilocularis | DNA topoisomerase 1 | 0.405754 | 1 | 1 |
Schistosoma mansoni | DNA topoisomerase type I | 0.405754 | 1 | 1 |
Echinococcus granulosus | DNA topoisomerase 1 | 0.405754 | 1 | 1 |
Mycobacterium leprae | Probable DNA topoisomerase I TopA (omega-protein) (relaxing enzyme) (untwisting enzyme) (swivelase) (type I DNA topoisomerase) ( | 0.002911 | 0 | 0.5 |
Leishmania major | DNA topoisomerase IB, large subunit | 0.299126 | 0.735311 | 1 |
Chlamydia trachomatis | DNA topoisomerase I | 0.002911 | 0 | 0.5 |
Trypanosoma brucei | DNA topoisomerase type IB small subunit | 0.198187 | 0.484744 | 0.659237 |
Echinococcus multilocularis | 0.0502161 | 0.117428 | 0.117428 | |
Wolbachia endosymbiont of Brugia malayi | topoisomerase IA, TopA | 0.002911 | 0 | 0.5 |
Loa Loa (eye worm) | DNA topoisomerase I | 0.405754 | 1 | 1 |
Mycobacterium ulcerans | DNA topoisomerase I | 0.002911 | 0 | 0.5 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0220261 | 0.0474506 | 0.0474506 |
Trichomonas vaginalis | prokaryotic DNA topoisomerase, putative | 0.002911 | 0 | 0.5 |
Schistosoma mansoni | DNA topoisomerase type I | 0.299126 | 0.735311 | 0.735311 |
Entamoeba histolytica | DNA topoisomerase III, putative | 0.002911 | 0 | 0.5 |
Brugia malayi | Protein kinase domain containing protein | 0.0220261 | 0.0474506 | 0.0474506 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
CC50 (ADMET) | = 15 uM | Cytotoxicity against human MRC5 cells after 7 days by MTT assay | ChEMBL. | 18226428 |
IC50 (functional) | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum THAI/Thailand as [3H]hypoxanthine uptake after 24 hrs by semi-automated micro dilution | ChEMBL. | 18226428 | |
IC50 (functional) | Antimalarial activity after 24 hrs against chloroquine-resistant Plasmodium falciparum K1/Thailand by [3H]hypoxanthine uptake | ChEMBL. | 18226428 | |
IC50 (functional) | = 31.4 nM | Antimalarial activity after 24 hrs against chloroquine-resistant Plasmodium falciparum FcB1R/Colombia by [3H]hypoxanthine uptake | ChEMBL. | 18226428 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | 18226428 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.